Retail chatter around Cingulate spiked Tuesday after Phase 3 data confirmed that its lead candidate, CTx-1301, significantly improved ADHD symptoms in pediatric patients within five weeks of ...

Cingulate begins the last study it needs to submit its leading drug candidate, a precision-timed release ADHD medication, for Food and Drug Administration approval.

Cingulate Inc. (NASDAQ:CING) shares are surging, trading over 159% higher today. Here’s what’s driving the movement. Why It’s Moving: Cingulate’s stock is soaring following the ...

Targeting the cingulate gyrus, specifically the SCC, was one of the first evaluations of DBS in neuropsychiatric disease.

Cingulate Inc. (NASDAQ: CING) shares are on an upward trajectory Friday. It follows the announcement that Cingulate has been granted European Patent No. 3261625 for its flagship asset, CTx-1301 ...

Pharmaceutical company Cingulate appears to have bolstered its stockholders' equity enough to resolve an oustanding delisting warning from the Nasdaq.

KANSAS CITY, Kan., April 29, 2025 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery ...

Cingulate (CING) signed a joint commercialization agreement with Indegene for its lead drug candidate CTx-1301 to treat attention deficit/hyperactivity disorder ( (ADHD)).Cingulate said ...

Cingulate Inc. CING shares are surging, trading over 159% higher today. Here’s what’s driving the movement. Why It’s Moving: Cingulate’s stock is soaring following the announcement that ...